[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"supportive-care-in-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:supportive-care-in-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100643615","digital-support-for-multiple-myeloma-quality-of-life-100643615",false,"NCT07642362","Digital Support for Multiple Myeloma Quality of Life","Digital Support for Enhancing the Quality of Life of Patients With Multiple Myeloma: An Observational, Randomized, Prospective Study (DigiMyQoL)","DigiMyQoL","Inclusion Criteria:\n\n* Adult patients with newly diagnosed or relapsed\u002Frefractory multiple myeloma\n* Patients that are able to use the digital platform\u002Fapplication\n\nExclusion Criteria:\n\n* Patients that are not able to use the digital platform\u002Fapplication","ALL",{"count":19,"type":20},108,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform.\n\nSpecifically, the study will compare Patient-Reported Outcomes (PROs) and the associated improvement in side effects and quality of life achieved through appropriate personalized educational and supportive content.",[26,27,28,29],"Multiple Myeloma","Patient Reported Outcome (PRO)","Supportive Care in Cancer","Quality of Life",[31,32,33,34,35,36,37],"multiple myeloma","quality of life","qol","patient reported outcome","pro","digital oncology","supportive care","RECRUITING","2026-06-07",{"date":41,"type":42},"2026-06-11","ACTUAL",{"date":44,"type":42},"2025-02-27",{"date":46,"type":20},"2028-03",{"name":48,"class":49},"CareAcross","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":50},"100611119","living-well-program-impact-on-healthcare-costs-and-clinical-outcomes-in-breast-cancer-care-100611119","NCT07236437","Living Well Program: Impact on Healthcare Costs and Clinical Outcomes in Breast Cancer Care","Inclusion Criteria:\n\n1. Age 18+\n2. First time breast cancer diagnosis\n3. Established with a Cedars-Sinai Surgical or Medical Oncologist for cancer care and is within 30 days of starting or having started adjuvant or neoadjuvant therapy\n4. Prognosis of greater than 1 year\n5. Breast cancer staging of II-IV\n6. Moderate to severe anxiety (GAD-7 \\>= 10)\n7. English language proficiency\n8. Smartphone and ability to use the application as assessed by study staff (IG only)\n9. Signed dated informed consent form (ICF) within 30 days of diagnosis (IG only)\n\nExclusion Criteria:\n\n1. Prior history of different cancer diagnosis or recurrence of the same cancer\n2. Serious mental illness evidenced by patient self-report, chart review and\u002For diagnosis codes\n3. Presence of suicidal ideation as measured by the Ask Suicide-Screening Questions (ASQ) or a history of suicide attempts as evidenced by self-report or chart review\n4. Current active addiction (drugs, alcohol, etc.) evidenced by Opioid Risk Tool, chart review and\u002For diagnosis codes","FEMALE","18 Years",{"count":60,"type":20},50,[23],"The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer?\n\nThe study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.",[64,28,65],"Anxiety","Depression",[64,67,68,69,70],"Breast Cancer","Telecoaching","Telehealth","Supportive Care","NOT_YET_RECRUITING","2025-11-14",{"date":74,"type":42},"2025-11-19",{"date":76,"type":20},"2025-11-15",{"date":78,"type":20},"2027-11-15",{"name":80,"class":81},"Scott A. Irwin, MD, PhD","OTHER",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":5},"100568771","the-4d-picture-project-evaluating-metro-mapping-as-a-method-to-support-shared-decision-making-in-oncology-100568771","NCT06685562","The 4D PICTURE Project: Evaluating Metro Mapping As a Method to Support Shared Decision Making in Oncology","The 4D PICTURE Project - Design-based Data-driven Decision-support Tools: Producing Improved Cancer Outcomes Through User-Centered Research","Inclusion Criteria:\n\n* Adult (\\>18 years) (either being the patient or the informal caregiver in the care path)\n* Prostate cancer, breast cancer or melanoma cancer\n* Able to provide consent\n* Able to speak Dutch, Danish, Spanish, Catalan\n\nExclusion Criteria:\n\nA potential subject who does not meet any of the above criteria will be excluded from participation in this study. There are no further specified exclusion criteria.",{"count":90,"type":20},500,"OBSERVATIONAL","The goal of this observational study is to evaluate the impact of MetroMapping (a service design methodology) on Shared Decision Making in cancer care paths. The goal is to improve Shared Decision Making and make cancer care paths less overwhelming. The study will include adult participants (older than 18 years) with breast, prostate and melanoma cancers. The main question is How does the implementation of MetroMapping improve Shared Decision Making in cancer care paths.\n\n500 patients, across the Netherlands, Spain, and Denmark, will be enrolled in a pre- and posttest phase. Including 100 breast cancer, 100 prostate cancer, and 50 melanoma patients per phase. To further understand patient experiences, the researchers will audio-record and transcribe the Shared Decision Making consultation of a subset of participants (10 per tumor type per country). A total of 120 audio-recordings across both study phases will be collected. In the post-test phase, a personal care path navigator will be created and the researchers will conduct interviews with 3 patients per care path and interviews with clinicians (12 per country, a total of 36) to assess their experiences with MetroMapping.\n\nThe study is a pre-test and post-test multiple methods design, gathering both quantitative and qualitative data across care paths in the Netherlands, Spain and Denmark. Quantitative data will be collected via electronic (Castor EDC \\& RedCap) and paper questionnaires. Participants will receive the first set of questionnaires, one week after their decision-making consult. Encompassing the following questionnaires (I-SHARE for perceived Shared Decision Making, Control Preferences Scale for the perceived roles in the actual decision, Decisions Made, Decisional Comfort Scale, SCIP B Information Provision, PEPPI-5 Perceived Efficacy in Patient-Physician Interactions, Trust in Oncologists, Health Literacy) and for the cost-effectiveness analysis for our partner (UMIT TIROL) the EORTC QLU C10-D and EQ-5D5l will be added to assess utilities. In the post-test participants will receive the second set of questionnaires, 6 months after the first set of questionnaires. This set encompasses (Healthcare Integration INTEGrate, Person Centered Coordinated Care Experiences P3CEQ, Decisional Regret Scale, Trust in Oncologists, EORTC QLU-C10D, EQ-5D5L, Productivity Cost Questionnaires.\n\nThis study includes a pre-implementation comparison group, and results will be compared with post-implementation outcomes.\n\nParticipants will complete the questionnaires and provide demographic and clinical data (consent for sharing medical file is asked) and an audio-recording of their consultation will be made. Participants in the post-phase will participate in interviews about their experiences with the implementation of MetroMapping.\n\nThe audio-recordings will be transcribed and analyzed using the OPTION and 4SDM coding instruments. Data will be analyzed using both univariate and multivariate statistical methods. Transcript of audio-recordings will be analyzed using thematic analysis and the coding instruments.",[94,95,96,28],"Breast Cancer Patients","Melanoma Cancer","Prostate Cancer",[98,99,100,101,102],"MetroMapping","Shared Decision Making","Oncology","Service design","care path redesign","2024-11-11",{"date":105,"type":42},"2024-11-12",{"date":107,"type":42},"2023-12-20",{"date":109,"type":20},"2026-05-20",{"name":111,"class":81},"Leiden University Medical Center"]